Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

It’s not yet known how many people have gotten sick in the Texas measles outbreak, but there are at least 215 confirmed cases since late January.

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A Lancet study shows promising results for an annual HIV prevention injection, lenacapavir. In Stage 1 trials, 40 HIV-negative participants had no significant side effects ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...